Inactive Instrument

Highlights Cytosorbents Corp OTC Bulletin Board

Equities

CTSO

US23283X1072

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Cytosorbents Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Earnings Flash (CTSO) CYTOSORBENTS Reports Q4 Revenue $8.7M, vs. Street Est of $9.8M	Mar. 14	MT
Cytosorbents Corporation Reports Excellent Outcomes from A Groundbreaking Randomized Controlled Trial Using Cytosorb® Blood Purification During Heart Transplant, Recently Published in the European Society of Cardiology Journal, Esc Heart Failure	Jan. 17	CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday	Dec. 28	MT
Cytosorbents Corporation Provides Update on the Star-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation	Dec. 28	CI
Earnings Flash (CTSO) CYTOSORBENTS Posts Q3 Revenue $8.8M, vs. Street Est of $9.32M	Nov. 09	MT
Cytosorbents Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Cytosorbents Says CytoSorb Product Received Expanded Registration to Treat Shock in Brazil	23-08-31	MT
CytoSorbents Corporation Completes U.S. and Canadian Star-T Pivotal Trial	23-08-14	CI
Earnings Flash (CTSO) CYTOSORBENTS Reports Q2 Revenue $9.4M, vs. Street Est of $10.2M	23-08-01	MT
Cytosorbents Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-01	CI
Cytosorbents, Humedics to Joint Promote Liver Disease Technologies	23-07-11	MT
Earnings Flash (CTSO) CYTOSORBENTS Reports Q1 Revenue $9.4M, vs. Street Est of $8.7M	23-05-02	MT
Cytosorbents Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-02	CI
Cytosorbents Says STAR-T Trial Enrolls 80 Patients, Reaches Second of Three Milestones	23-04-20	MT
Cytosorbents’ Pivotal Star-T Trial Reaches Second Key Milestone with 80 Patients Enrolled	23-04-20	CI
Cytosorbents Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Earnings Flash (CTSO) CYTOSORBENTS Posts Q4 Revenue $34.7M, vs. Street Est of $8.75M	23-03-09	MT
CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial	23-01-23	CI
Cytosorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal Star-T Trial as Planned Without Modifications	22-12-21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cytosorbents Corp OTC Bulletin Board

Equities

CTSO

US23283X1072

Highlights

Filters